31.01.2013 • NewsDow ChemicalQ4 2012sales and profits

Dow Chemical Q4 Profit Misses View

Dow Chemical posted lower-than-expected adjusted profit on Thursday, as demand withered for polyurethane and chlorine around the world, especially in China and Europe.

For the fourth quarter, the net loss widened to $716 million, or 61 cents per share, from $20 million, or 2 cents per share, in the year-earlier quarter.

Excluding one-time items, the company earned 33 cents during the quarter. By that measure, analysts expected 34 cents per share, according to Thomson Reuters I/B/E/S.

Sales fell 1% to $13.92 billion. Analysts looked for sales of $13.69 billion.

Repairs and shutdowns to facilities that make chlorine dented sales of the crucial chemical. Dow Chemical is the world's largest chlorine producer.

Results were especially weak for polyurethane foams, coatings and paints, and electronic materials.

The sharpest drop in volume, the physical amount of product sold, came in Europe, draining overall results.

"Weak volumes in Europe definitely held them back," Deutsche Bank analyst David Begleiter said of Dow Chemical's results.

China also proved a weak spot. "The second half of 2012 saw significant deterioration in the markets we serve, particularly in China," Dow Chemical Chief Executive Andrew Liveris said in a statement.

In an interview on the CNBC cable news channel on Thursday morning, Liveris said he expects sales in China to improve in 2013.

Last fall, the company said it was worried more about deteriorating sales in China than the U.S. fiscal crisis.

Dow Chemical took a $990 million charge in the quarter, part of a plan announced in October to lay off 5% of its workforce, close 20 plants and write down the value of its underperforming lithium ion battery business.

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.